3D Systems & Theradaptive Establish Commercial Partnership to Advance Orthopedic & Soft Tissue Repair Using Breakthrough Regenerative Therapeutics
Theradaptive’s proprietary protein-engineering platform produces targeted therapeutics that can be used to coat implants.
The companies intend to deliver a novel approach to promote bone and tissue growth using Theradaptive’s unique protein-based material-binding variants to coat 3D Systems’ 3D-printed medical devices. This solution has the potential to provide patients with an opportunity for improved healing and thus better outcomes.
Theradaptive's Founder, Luis M. Alvarez, Ph.D., conceived of the protein-engineering technology after witnessing extremity injuries that resulted in delayed amputations among servicemembers. His subsequent research into bone and tissue regeneration at MIT focused on addressing the limitations associated with existing regenerative medicine approaches such as achieving anatomically precise outcomes and ultra-persistent local delivery of therapeutics. The first applications of this technology have already earned three Breakthrough Medical Device designations from the FDA to address degenerative disc disease and spinal fusion.
As the original innovator of 3D printing and a pioneer in personalized healthcare solutions, 3D Systems has worked with surgeons for over a decade to plan more than 150,000 patient-specific cases, and additively manufacture more than two million implants.
https://finance.yahoo.com/news/3d-systems-theradaptive-establish-commercial-201000761.html
ارسال به دوستان